期刊
ONCOLOGY LETTERS
卷 22, 期 1, 页码 -出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2021.12807
关键词
six-transmembrane epithelial antigen of the prostate 1; c-Myc; G1 arrest; liver cancer; hepatocellular carcinoma; cancer therapeutics
类别
资金
- Japan Society forfor the Promotion of Science [19K08397]
- Grants-in-Aid for Scientific Research [19K08397] Funding Source: KAKEN
STEAP1 is an ideal target in cancer therapeutics, and its upregulation in liver cancer is associated with poor clinical outcomes. Silencing STEAP1 inhibits cell proliferation and induces G1 arrest by suppressing c-Myc expression.
Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) has emerged as an ideal target in cancer therapeutics. However, the functions of STEAP1 in liver cancer remain unexplored. The current study aimed to characterize the biological roles of STEAP1 in liver cancer. STEAP1 expression was upregulated in tumor tissues, and high STEAP1 expression was associated with poor clinical outcomes in patients with liver cancer, according to several publicly available datasets. STEAP1 silencing using small interfering RNA inhibited cell proliferation and was accompanied by G(1) arrest induced by the suppression of cyclin D1 and the promotion of p27. STEAP1 silencing suppressed c-Myc expression, which was identified as a component in STEAP1 signal transduction by mining publicly available datasets and was then confirmed by PCR array. In conclusion, the knockdown of STEAP1 in liver cancer cell lines led to inhibition of cell proliferation involving G(1) arrest by suppressing c-Myc. The present study provides a preclinical concept for STEAP1 as a druggable target in liver cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据